The landmark FDA approval of Biogen / Eisai’s aducanumab (Aduhelm) in 2021 has had a minimal effect on treatment dynamics in AD owing to the lack of reimbursement and the controversy surrounding…
Although multiple guidelines recommend treating post-traumatic stress disorder (PTSD) with psychotherapy first, such an approach does not suffice for many patients, necessitating the use of…
Migraine, which afflicts approximately 73 million people in the major pharmaceutical markets, according to Clarivate Epidemiology, is a heterogeneous condition requiring individualized treatment…
Postherpetic neuralgia (PHN) is characterized by itching, numbness, and burning, as well as stabbing, shooting, or shock-like pain. PHN is managed with multiple established, generic antiepileptic…
Obesity is a significant and growing public health concern in the G7 countries. The body of evidence highlighting the medical and economic impact of obesity on society is steadily increasing…
Ten new brands entered the Parkinson’s disease (PD) market over the last decade (e.g., Acorda’s Inbrija, Sunovion’s Kynmobi, Neurocrine’s Ongentys), and additional new options are advancing…
The renal cell carcinoma (RCC) therapy market is rapidly evolving and experiencing substantial growth, largely driven by the increasing uptake of immune checkpoint inhibitors. Combination regimens…
In 2022, sales of branded biologics in ophthalmology exceeded $9.6 billion in the major pharmaceutical markets under study (United States, EU5, and Japan). Throughout our 2022-2032 forecast period…
The small-cell lung cancer (SCLC) treatment landscape is dominated by chemotherapy and chemoradiotherapy. In the last 30 years, only two immunotherapies have been approved in this indication:…
In 2022, sales of branded biologics for respiratory indications totaled about $2.3 billion in the major pharmaceutical markets under study (United States, EU5, and Japan). Throughout our 2022-2032…
In 2022, sales of insulins at the ex-manufacturer price level exceeded $16 billion in the major pharmaceutical markets under study (United States, EU5, and Japan). Throughout our 2022-2032 forecast…
In 2022, sales of erythropoiesis-stimulating agent (ESA) brands and biosimilars at the ex-manufacturer price level totaled more than $3.6 billion in the major pharmaceutical markets under study (…
In 2022, sales of branded biologics in immunology exceeded $65 billion in the major pharmaceutical markets under study (United States, EU5, and Japan). Major-market sales of biosimilars in this…
In 2022, sales of branded MAb biologics in oncology exceeded $43 billion in the major pharmaceutical markets (United States, EU5, and Japan), and sales of biosimilars totaled approximately $5.6…
A wide array of drugs are available to treat osteoporosis. These drugs are generally effective in reducing patients’ risk of fracture and are well tolerated. Oral bisphosphonates, especially…